Abstracts tagged "Puberty"

Abstract Number: 1846 • 2018 ACR/ARHP Annual Meeting
Menarchal Status at Diagnosis and Final Height in Females with Childhood-Onset Systemic Lupus Erythematosus
Watchareewan Sontichai¹, Daniela Dominguez¹, Lawrence Ng¹, Deborah M. Levy¹, Jonathan Wasserman², Earl Silverman¹ and Linda Hiraki¹, ¹Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ²Division of Endocrinology, The Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: The diagnosis of systemic lupus erythematosus (SLE) in childhood affects growth due to disease and therapy. To date, there are few studies of final…
Abstract Number: 1278 • 2017 ACR/ARHP Annual Meeting
Growth and Puberty in Juvenile Dermatomyositis a Longitudinal Multinatinal Cohort Study
Ellen Nordal^1,2, Angela Pistorio³, Marite Rygg³, Gabriella Giancane⁴, Michaël Hofer³, Jose Antonio Melo-Gomes⁴, Blanca Bica⁴, Ximean Norambuena⁴, Valda Stanevicha³, Rebecca ten Cate⁵, Olga Vougiouka⁴, Jurgen Brunner⁴, Guenther Dannecker⁴, Polyxeni Pratsidou-Gertsi⁴, Gabriele Simonini⁴, Helen Venning⁴, Serena Pastore⁴, Angelo Ravelli⁶, Alberto Martini⁷ and Nicolino Ruperto⁷, ¹Department of Pediatrics, University Hospital of Northern Norway, Tromsø, Norway, ²Department of Clinical medicine, UIT, the Arctic University of Norway, Tromsø, Norway, ³Istituto Giannina Gaslini - Pediatria II, Reumatologia - PRINTO, Genoa, Italy, ⁴Istituto Giannina Gaslini - Pediatria II, Reumatologia - PRINTO, Genova, Italy, ⁵Pediatric Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁶University of Genova, IRCCS Istituto Giannina Gaslini, Genova, Italy, ⁷Istituto Giannina Gaslini, Genoa, Italy
Background/Purpose: Children with juvenile dermatomyositis (JDM) are at risk of growth failure and delayed puberty because of inflammatory disease activity and side effects of corticosteroid…
Abstract Number: 5 • 2017 Pediatric Rheumatology Symposium
Effects of Puberty on Systemic Lupus Erythematosus: Results of a multi-center prospective longitudinal observational study in children entering puberty with SLE
Kathleen O'Neil¹, Hermine Brunner², Andrew Zeft³, Anne Stevens⁴, Suzanne Li⁵, Tracey Wright⁶, Emily von Scheven⁷, B. Anne Eberhard⁸, C. Egla Rabinovich⁹ and Deborah M. Levy¹⁰, ¹Pediatrics, Indiana University, Indianapolis, IN, ²Rheumatology, PRCSG, Cincinnati, OH, ³Pediatrics Rheumatology, Cleveland Clinic, Cleveland, OH, ⁴University of Washington, Department of Pediatrics, Seattle, WA, ⁵Pediatrics, Joseph M Sanzari Children’s Hospital, Hackensack Meridian Health, Hackensack, NJ, ⁶Pediatrics/Rheumatology, University of TX Southwestern, Dallas, TX, ⁷Division of Rheumatology, Department of Pediatrics, University of California San Francisco, San Francisco, CA, ⁸Cohen Children's Medical Center of New York, New Hyde Park, NY, ⁹Pediatric Rheumatology, Duke University Medical Center, Durham, NC, ¹⁰Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: Lupus often presents during puberty, and when it affects pre-pubertal children, disease activity is thought to increase at puberty. Sex hormones play some role…
Abstract Number: 1254 • 2013 ACR/ARHP Annual Meeting
Prevalence Of Antinuclear Antibodies In Schoolchildren Across Puberty and Possible Relationship With Musculoskeletal Pain. A Longitudinal Study
Francesca Sperotto¹, Sara Brachi², Mara Seguso³, Fabio Vittadello¹ and Francesco Zulian⁴, ¹Department of Pediatrics, University of Padua, Padua, Italy, ²Department of Pediatrics, University of Ferrara, Ferrara, Italy, ³Department of Laboratory Medicine, University of Padua, Padua, Italy, ⁴PRINTO, Genoa, Italy
Background/Purpose: Antinuclear antibodies (ANA) are frequently found in children with connective tissue diseases but can also be found in healthy individuals even in absence of…

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.